Confused and disoriented pets? Dementia is not just for humans
"Olli has had dementia for a few years," says owner Ute Hausmann. She has completely adjusted to his needs, caring for, nurturing, looking after and encouraging the animal that has been living with her and her husband in the Rheinisch-Bergisch district near Cologne for 11 years. Because: "Olli is dearly loved."
Dementia widespread among older dogs and cats
According to Holger Volk, a doctor at the University of Veterinary Medicine Hanover, dementia is common among dogs and cats of an advanced age.
He says that about one in three dogs aged 12 to 13 years show clinical symptoms.
By the age of 15 to 16, two out of three dogs are affected by "canine cognitive dysfunction syndrome."
And among very old cats at about 16 years of age, around 50% have dementia, known as "feline" syndrome. So, all in all, a "huge number," he says.
Early intervention is very important. "When pet owners notice abnormalities, it is often almost too late," says Volk, who heads the hospital for small animals.
The disease is difficult to diagnose because the signs vary and dementia develops progressively. It is usually accompanied by other illnesses and not easily separated from "normal" degenerative signs of old age.
What causes dementia and what to watch for?
Changes in an animal's brain metabolism, inflammation and protein deposits all cause nerve cells to no longer work properly. Those changes make an animal slow down and some forget practised commands. They may get confused and no longer sleep well – and there are also behavioural changes.
"Loner behaviour and withdrawal" are examples Volk cites. Joint pain and dental disease are common.
Prevention can help. Measures can include a suitable low-sugar diet – with certain fatty acids that work as energy sources for older animals and prevent inflammatory reactions.
If dementia is diagnosed, special food is definitely part of a treatment strategy. Exercise and mental stimulation are also key.
"There are not many medications available" – except for a stimulant to help with persistent poor sleep or a means to promote blood circulation, says Volk.
So it is important to observe your animal carefully for any changes.
Cats: Harder to watch closely
Cats like to do their own thing – and therefore tend to slip under the radar and out of sight. But signs of dementia in cats can include appearing anxious, becoming less active and interacting less, the veterinarian says.
It is also very common for cats to meow loudly, almost scream at night, a sign the animal is trying to locate itself.
A cat may also struggle to find its litter tray – just as a normally house-trained dog may stop indicating when it has to go and instead relieve itself in the home, according to the animal welfare foundation Four Paws.
Dementia brings changes not only for the affected animals, but also for their families. But with patience and the right care, the progression of the incurable disease can be slowed down.
As for the senior pug Olli, exercise and a routine are very important. Owner Hausmann massages her pug's aching hind legs every morning. Then she takes him out two to three times a day – always the same familiar short distances and very slowly.
"It helps him to cope," she says.
Even a curb can pose a challenge. After the short walk, the 74-year-old lifts the 9-kilogram bundle onto the sofa at home. "Olli used to be very boisterous and lively. Now he's slow, unsure of himself and always wants to be where I am, constantly following me around."
Engaging with other four-legged friends is out of the question.
"He doesn't want anything to do with other dogs any more. He used to be in a good mood, was very interested in females, but now he doesn't like any contact at all."
At night, her pug often wakes up and seems completely lost. "Olli has a cautious, gentle character, he's not aggressive and luckily he still goes to the toilet outside," says Hausmann.
He manages to make himself noticed – and then he's out the front door and into the garden.
Hausmann, a former nursery school teacher who knows her pug inside out, doesn't miss a beat. Converted into human years, Olli is almost 100 years old.
Growing awareness of older animals' needs
Veterinarian Volk has observed that many pets are now living to a ripe old age, and this has led to a growing awareness of the issue.
However, he says doctors often only diagnose and treat concomitant diseases such as heart, kidney or joint problems. "The brain is not the focus of attention, but it is becoming more and more so."
He knows that it often helps pet owners when they receive clarity and a confirmed diagnosis of dementia.
Similar to humans, the same applies to dogs and cats: Age is a risk factor, but not a cause of dementia, he says. "We need to work much harder on prevention. A happy life includes a healthy brain."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Alzheimer's may be delayed through lifestyle changes, new studies show
Although her grandfather had dementia when he died, Kristin Richardson hadn't worried much about her brain until a lab test revealed that she was positive for APOE4, a gene that has been linked to a higher risk of developing Alzheimer's disease. That was seven and a half years ago. Richardson, now 51, remembers crying when she got the news. 'I was terrified,' she said. 'It's a horrible, horrible disease with no cure.' So Richardson, a business owner in Richmond, Virginia, decided to make whatever changes she could to reduce her risk of the disease. 'I do what I can to get enough sleep. I keep active. I try to eat well and maintain a healthy weight, and I'm always working my brain to learn new things,' she said. Two new studies being presented at the Alzheimer's Association meeting Monday in Toronto may give some hope to Richardson and others who carry a genetic risk for the disease. Both new studies build on previous evidence that diet, certain brain training exercises and physical activity can delay the loss of memory and slow the decline of other cognitive abilities. One study looked at the impact of walking on 2,985 Black and white older adults who were tested for APOE status and were followed for 10 years. Each year, the participants were questioned about the amount of walking they did, and at multiple points during the follow-up period, their cognitive status was evaluated with standardized exams. Overall, participants with the APOE4 gene mutation showed steeper declines in cognition compared with those with other forms of the gene that don't raise the risk of Alzheimer's. While walking appeared to have a protective effect on all the participants, it was strongest among those with APOE4. The risk of developing Alzheimer's among those with two copies of APOE4 is 12 times that of women with none and four times that of men with none, said the study's senior author, Cindy Barha, an assistant professor of neuroscience at the University of Calgary and Canada Research chair in neuroscience, brain health and exercise. That changed significantly if people walked. Overall, women benefited more. A 10% higher amount of self-reported walking was associated with a 4.7% increase in complex thinking performance over time in women and a 2.6% increase in men. Among APOE4 carriers, men appeared to benefit more. A 10% higher amount of self-reported walking was associated with an 8.5% increase in global cognitive performance over time in women and a 12% increase in men. That was a surprise to the researchers, who expected that women would continue to benefit more. Walking seems to keep brains healthier by pumping up levels of brain-derived neurotrophic factor (BDNF), a protein that's known to support the health of brain cells, Barha said. Other proteins in the brain may be involved, as well. 'BDNF is like fertilizer for your brain that is naturally produced, especially when you are being physically active, such as when you are walking,' Barha said. 'It helps brain cells survive, grow and form stronger connections; this supports memory, learning and mood, especially in the hippocampus, which is the brain's memory center.' A limitation of the study is that it didn't track how fast or how frequently the participants walked. Dementia risk modified through lifestyle The second international study, led by researchers in Finland, found that a combination of lifestyle modifications could also benefit people with the APOE4 variation more than those with other mutations. The study included 2,469 participants from France, Japan and Finland who were randomly assigned to receive multi-focus lifestyle interventions or not. Among the participants were 709 APOE4 carriers. Included in the lifestyle modifications were: Cognitive training, either computer-based or with paper and pencil. Physical activity, including group-based physical group exercise sessions lasting 90 minutes and an exercise program supervised by physiotherapists at the gym. Dietary counseling. A preliminary analysis revealed that the benefit of the intervention was greater among the APOE4 carriers. Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway is that the risk for dementia, even in people with genetic predisposition, can be modified through lifestyle. There was about a fourfold greater benefit in those who were positive for APOE4, said Lehtisalo, who is also a visiting researcher at the University of Eastern Finland. The hope is that future research will reveal whether there is a specific window of time during which the modifications are more effective, she said. Dr. Cynthia Boyd, a professor of medicine and director of the division of geriatric medicine and gerontology at Johns Hopkins Medicine, said the studies show 'there is something concrete we can all do to decrease the risk of cognitive decline.' 'Walking and other lifestyle modifications can be protective for the brain,' said Boyd, who wasn't involved in the new research. Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, said that to optimize brain and cognitive health, it's a good idea for everyone, regardless of genetic risk, to engage in physical activity, maintain a good diet and monitor other risk factors linked to dementia. 'Sometimes initiating new healthy behaviors is difficult for people," Brickman said. "Knowledge of being at increased risk for Alzheimer's disease by virtue of having an APOE4 allele may help inspire or motivate lifestyle changes to mitigate that risk.' This article was originally published on
Yahoo
6 hours ago
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
Yahoo
14 hours ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data